

- Claim 45: The expression vector of claim 42, further comprising a nucleic acid molecule which encodes an HLA molecule.
- Claim 46: The expression vector of claim 45, wherein said HLA molecule is HLA-Cw6 or HLA-A29.
- C12 Claim 47: A kit useful in transfecting or transforming a cell comprising:
 (i) the isolated nucleic acid molecule of claim 41, and
 (ii) an isolated nucleic acid molecule which encodes an HLA molecule.
- Claim 48: The kit of claim 47, wherein said HLA molecule is HLA-Cw6 or HLA-A29.
- Claim 49: An isolated nucleic acid molecule which encodes a GAGE tumor rejection antigen precursor, the complementary sequence of which hybridizes, at the following conditions: 1 M NaCl, 1% SDS, 10% dextran sulfate for 18 hours at 65°C, followed by two washes at room temperature for 5 minutes in 2xSSC, and one wash for 30 minutes in 2xSSC, 0.1% SDS, at 65°C.
- Claim 50: The isolate nucleic acid molecule of claim 41, the nucleotide sequence of which is set forth in SEQ ID NO: 14.

REMARKS

Entry of the foregoing amendment is requested.

With respect to the examiner's remarks, at page 2, point 1, the following responses are necessary.

With respect to the figures, i.e., figures 3, 4, 5 & 8 (and figure 8), the examiner states the amendments were not entered "because no attachments were received."

The attachments were received. Transmitted is a copy of the stamped, return receipt postcard indicating that the figures were received. Presumably, the USPTO lost the figures.